| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G/A |
| 12 Nov 2026 | 10-Q |
| 12 Nov 2026 |
8-K: Results of Operations and Financial Condition
— First patient dosed with ATR 1072 in the Corventis™ Phase 1/2 clinical trial in PRKAG2 syndrome — |
| 02 Nov 2026 |
8-K: Regulation FD Disclosure; Other Events
Exhibit 99.2 Atrium Therapeutics 2 November 2026 RNA L I S T E D www.atriumtherapeutics.com NASDAQ 1 |
| 27 Oct 2026 |
8-K: Other Events
Atrium Therapeutics Doses First Patient in Corventis™, the First Interventional Clinical Trial for People Living with PRKAG2 Syndrome |
| 09 Oct 2026 |
8-K/A: Other Events
As previously disclosed in the Original Form 8-K, on October 7, 2026, the Company entered into a securities purchase agreement with selected investors that qualify as “accredited investors” (collectively, the “PIPE Investors”), as define... |
| 08 Oct 2026 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of October 7, 2026, by and among Atrium Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the entities listed on Exhibit A attached to this Agreement... |
| 22 Sep 2026 |
Form 4: Younis Husam, Chief Scientific Officer
Gave up 11,216 shares to cover exercise price or tax ($100K) |
| 22 Sep 2026 |
Form 4: Hughes Steven George, Chief Medical Officer
Gave up 21,459 shares to cover exercise price or tax ($192K) |
| 22 Sep 2026 |
Form 4: Flanagan W. Michael, Director
Gave up 22,812 shares to cover exercise price or tax ($204K) |
| 22 Sep 2026 |
Form 4: Boyce Sarah, Director
Gave up 126,418 shares to cover exercise price or tax ($1.13M) |
| 22 Sep 2026 |
Form 4: Kenney Stephanie, See Remarks
Gave up 2,375 shares to cover exercise price or tax ($21.3K) |
| 22 Sep 2026 |
Form 4: Gallagher Kathleen P., Director
Gave up 11,632 shares to cover exercise price or tax ($104K) |
| 22 Sep 2026 |
Form 4: Winslow Brendan R., Chief Financial Officer
Gave up 6,742 shares to cover exercise price or tax ($60.3K) |
| 22 Sep 2026 |
Form 4: Hoyos Rocio Martin, Chief Strategy Officer
Gave up 8,320 shares to cover exercise price or tax ($74.5K) |
| 14 Aug 2026 | SCHEDULE 13G |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 13 Aug 2026 | 10-Q |
| 13 Aug 2026 |
8-K: Results of Operations and Financial Condition
— IND clearance for ATR 1072 and launch of Corventis Phase 1/2 trial in |
Loading...